Skip to main content
Clinical Trials/NCT06221722
NCT06221722
Recruiting
N/A

Evaluation of Brain Connectivity Function in Predicting Therapeutic Effects in Patients With Refractory Constipation: a Multicenter, Prospective, Cohort Study

Xijing Hospital of Digestive Diseases3 sites in 1 country150 target enrollmentNovember 1, 2023

Overview

Phase
N/A
Intervention
BOLD-fMRI
Conditions
Constipation - Functional
Sponsor
Xijing Hospital of Digestive Diseases
Enrollment
150
Locations
3
Primary Endpoint
Brain functional connectivity changes in BOLD-fMRI examination in refractory constipation before and after fluoxetine treatment
Status
Recruiting
Last Updated
9 months ago

Overview

Brief Summary

The goal of this observational study is to identify the characteristics of brain functional connectivity in refractory constipation and fluoxetine-sensitive patients. The main questions it aims to answer are:

  • Investigating the alterations in brain functional connectivity in patients with refractory constipation and fluoxetine-sensitive patients
  • Assessing the predictive value of brain functional connectivity regarding the efficacy of fluoxetine and standard protocol treatments for constipation.

Participants will receive:

  • Standard physiological and psychological assessments of constipation
  • BOLD-fMRI tests
  • Standard protocol and fluoxetine treatment

If there is a comparison group: Researchers will compare:

Refractory group/Fluoxetine sensitive group to see the specific brain alterations.

Registry
clinicaltrials.gov
Start Date
November 1, 2023
End Date
September 1, 2026
Last Updated
9 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Xijing Hospital of Digestive Diseases
Responsible Party
Principal Investigator
Principal Investigator

Zhifeng Zhao, PhD

Dr.

Xijing Hospital of Digestive Diseases

Eligibility Criteria

Inclusion Criteria

  • 18≤ age ≤ 45 years old
  • Right-handed
  • Patients diagnosed as functional constipation according to the Rome IV criteria
  • Informed consent of patients

Exclusion Criteria

  • Complicated with gastrointestinal organic disease or significant functional abnormalities (tuberculosis, polyps, Crohn's disease, tumors, congenital megacolon, pelvic floor muscle relaxation, abnormal colonic transit test, etc.)
  • Long-term intense exercise (continuous exercise for more than 8 hours per week, such as marathon runners or triathletes)
  • No history of chronic pain, no recent major trauma
  • Drug abuse or tobacco dependence (half a pack or more per day)
  • Combined hypothyroidism and Parkinson's disease
  • Patients with confirmed mental illness or neurological disorders who take psychotropic drugs, analgesics or hormones
  • History of abdominal surgery (appendectomy, hysterectomy, or cholecystectomy)
  • Contraindications to functional magnetic resonance imaging (claustrophobia, metal implants)
  • Pregnant or lactating women with constipation after delivery
  • Patients with other benign and malignant tumors and autoimmune diseases

Arms & Interventions

Refractory constipation: fluoxetine sensitive

Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet. After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with effective treatment of constipation symptoms.

Intervention: BOLD-fMRI

Refractory constipation: fluoxetine sensitive

Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet. After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with effective treatment of constipation symptoms.

Intervention: Regular treatment of functional constipation

Refractory constipation: fluoxetine sensitive

Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet. After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with effective treatment of constipation symptoms.

Intervention: fluoxetine

Refractory constipation: fluoxetine insensitive

Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet. After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with ineffective treatment of constipation symptoms.

Intervention: BOLD-fMRI

Refractory constipation: fluoxetine insensitive

Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet. After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with ineffective treatment of constipation symptoms.

Intervention: Regular treatment of functional constipation

Refractory constipation: fluoxetine insensitive

Functional constipation patients maintained at least 3 months of continuous regular therapy with ineffective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet. After 3 months of regular treatment, patients received fluoxetine therapy for 4-week with ineffective treatment of constipation symptoms.

Intervention: fluoxetine

Non-refractory constipation

Functional constipation patients maintained at least 3 months of continuous regular therapy with effective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.

Intervention: BOLD-fMRI

Non-refractory constipation

Functional constipation patients maintained at least 3 months of continuous regular therapy with effective treatment. The treatment included the utilization of osmotic laxatives, stimulant laxatives, prosecretory agents, and a high-fibre diet.

Intervention: Regular treatment of functional constipation

Health Control

Volunteers without symptoms of constipation

Intervention: BOLD-fMRI

Outcomes

Primary Outcomes

Brain functional connectivity changes in BOLD-fMRI examination in refractory constipation before and after fluoxetine treatment

Time Frame: 1-week pre and 4-week post of fluoxetine treatment

BOLD-fMRI tests before and after fluoxetine treatment

Secondary Outcomes

  • Changes in PAC-QOL self-assessment scores from baseline(1-week pre and 4-week post-fluoxetine treatment.)
  • Changes in GAD-7 self-assessment scores from baseline.(1-week pre and 4-week post-fluoxetine treatment.)
  • Changes in PHQ-15 self-assessment scores relative to baseline.(1-week pre and 4-week post-fluoxetine treatment.)
  • Changes in PHQ-9 self-assessment scores since baseline.(1-week pre and 4-week post-fluoxetine treatment.)
  • Changes in KESS self-assessment scores from baseline.(1-week pre and 4-week post-fluoxetine treatment.)

Study Sites (3)

Loading locations...

Similar Trials